BAD HOMBURG & KONSTANZ, Germany--(BUSINESS WIRE)--Feb. 17, 2006--ALTANA AG (NYSE:AAA) (FWB:ALT) (GER:ALT) has announced today that the indication of Alvesco(R) (ciclesonide), a novel inhaled corticosteroid (ICS), has been extended to treat mild to severe persistent asthma in adolescent patients ages 12 and older. Following this European Mutual Recognition Variation Procedure national marketing authorizations will succeed.
